NanOlogy

NanOlogy is pioneering a novel intratumoral drug delivery platform to improve outcomes in solid tumors. Its proprietary Purcision™ technology creates excipient-free, large surface area microparticles (LSAMs) that act as a local drug depot, aiming to enhance tumoricidal effect and immunomodulation while drastically reducing systemic toxicity. With lead assets LSAM-PTX and LSAM-DTX having completed initial clinical trials, the company is positioned to address a significant unmet need across the spectrum of local and metastatic disease. The leadership team combines deep oncology drug development and commercial experience.

Purcision™ particle engineering technology that uses supercritical fluid CO2 to create Large Surface Area Microparticles (LSAMs) of pure drug for sustained-release intratumoral delivery.

NanOlogy competes in the intratumoral therapy space, which includes other drug-releasing depot technologies, oncolytic viruses, and gene therapies. Its differentiation lies in the excipient-free, pure-drug LSAMs capable of sustained release. Competition also comes from evolving systemic standard-of-care regimens and other minimally invasive ablative techniques.